[go: up one dir, main page]

MX2009007050A - Compuestos de carboxamida y su uso como inhibidores de calpaina. - Google Patents

Compuestos de carboxamida y su uso como inhibidores de calpaina.

Info

Publication number
MX2009007050A
MX2009007050A MX2009007050A MX2009007050A MX2009007050A MX 2009007050 A MX2009007050 A MX 2009007050A MX 2009007050 A MX2009007050 A MX 2009007050A MX 2009007050 A MX2009007050 A MX 2009007050A MX 2009007050 A MX2009007050 A MX 2009007050A
Authority
MX
Mexico
Prior art keywords
carboxamide compounds
compounds
calpain inhibitors
carboxamide
tautomers
Prior art date
Application number
MX2009007050A
Other languages
English (en)
Inventor
Wilfried Lubisch
Wilfried Hornberger
Andreas Kling
Achim Moeller
Helmut Mack
Volker Nimmrich
Dietmar Seemann
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39226751&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009007050(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of MX2009007050A publication Critical patent/MX2009007050A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a compuestos de carboxamida novedosos y a su uso para la manufactura de un medicamento. Los compuestos de carboxamida son inhibidores de calpaína (cisteína proteasas dependientes de calcio). Por lo tanto, la invención también se refiere al uso de estos compuestos de carboxamida para el tratamiento de un trastorno asociado con una elevada actividad de calpaína. Los compuestos de carboxamida son compuestos de la Fórmula General (1), en donde R1, R2, R3b, RSb, W, Y, y X tienen los significados mencionados en las reivindicaciones y en la descripción, los tautómeros de los mismos y las sales farmacéuticamente adecuadas de los mismos. En particular los compuestos tienen la Fórmula General I-Aa' y l-A.a", en donde m, E, R1, R2, R3a, R3b, R2, Ry, Rw, y Rw6* tienen los significados mencionados en las reivindicaciones; n tiene un valor de 0 1 ó 2, los tautómeros de los mismos y las sales farmacéuticamente adecuadas de los mismos.
MX2009007050A 2006-12-29 2007-12-28 Compuestos de carboxamida y su uso como inhibidores de calpaina. MX2009007050A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06127369 2006-12-29
PCT/EP2007/064617 WO2008080969A1 (en) 2006-12-29 2007-12-28 Carboxamide compounds and their use as calpain inhibitors

Publications (1)

Publication Number Publication Date
MX2009007050A true MX2009007050A (es) 2009-09-23

Family

ID=39226751

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009007050A MX2009007050A (es) 2006-12-29 2007-12-28 Compuestos de carboxamida y su uso como inhibidores de calpaina.

Country Status (28)

Country Link
US (4) US8436034B2 (es)
EP (2) EP2439205B1 (es)
JP (1) JP5295976B2 (es)
KR (3) KR20150090282A (es)
CN (1) CN101616908B (es)
AR (2) AR064693A1 (es)
AT (1) ATE544758T1 (es)
AU (1) AU2007341232B2 (es)
BR (1) BRPI0721298A2 (es)
CA (1) CA2673580C (es)
CL (1) CL2007003879A1 (es)
CO (1) CO6190617A2 (es)
DK (1) DK2439205T3 (es)
EC (1) ECSP099476A (es)
ES (2) ES2381879T3 (es)
GT (1) GT200900186A (es)
IL (2) IL199447A (es)
MX (1) MX2009007050A (es)
MY (1) MY147780A (es)
NZ (2) NZ577719A (es)
PE (1) PE20081609A1 (es)
PL (1) PL2439205T3 (es)
PT (1) PT2439205E (es)
RU (2) RU2485114C2 (es)
TW (1) TWI405571B (es)
UA (1) UA100501C2 (es)
UY (1) UY30850A1 (es)
WO (1) WO2008080969A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY147780A (en) * 2006-12-29 2013-01-31 Abbvie Deutschland Carboxamide compounds and their use as calpain inhibitors
TWI453019B (zh) * 2007-12-28 2014-09-21 Abbvie Deutschland 甲醯胺化合物
AU2009281457A1 (en) * 2008-08-14 2010-02-18 Bayer Cropscience Ag Insecticidal 4-phenyl-1H-pyrazoles
TWI519530B (zh) * 2009-02-20 2016-02-01 艾伯維德國有限及兩合公司 羰醯胺化合物及其作為鈣蛋白酶(calpain)抑制劑之用途
US8236798B2 (en) 2009-05-07 2012-08-07 Abbott Gmbh & Co. Kg Carboxamide compounds and their use as calpain inhibitors
RS53164B (sr) * 2009-09-28 2014-06-30 F. Hoffmann-La Roche Ag Jedinjenja benzoksazepin pi3k inhibitora i njihovo korišćenje u lečenju raka
US9051304B2 (en) * 2009-12-22 2015-06-09 AbbVie Deutschland GmbH & Co. KG Carboxamide compounds and their use as calpain inhibitors V
US8598211B2 (en) * 2009-12-22 2013-12-03 Abbvie Inc. Carboxamide compounds and their use as calpain inhibitors IV
GB2505572B (en) 2010-04-30 2014-08-06 Abbott Cardiovascular Systems Catheter system providing step reduction for postconditioning
CA2819087A1 (en) * 2010-12-09 2012-06-14 AbbVie Deutschland GmbH & Co. KG Carboxamide compounds and their use as calpain inhibitors v
AR085013A1 (es) * 2011-01-26 2013-08-07 Sanofi Aventis Derivados de acido 3-heteroaroilamino-propionico sustituidos y su uso como sustancias farmaceuticas
WO2013126283A1 (en) 2012-02-20 2013-08-29 E. I. Du Pont De Nemours And Company Fungicidal pyrazoles
EP2834230A1 (en) 2012-04-03 2015-02-11 AbbVie Deutschland GmbH & Co KG Carboxamide compounds and their use as calpain inhibitors v
WO2014160810A1 (en) 2013-03-29 2014-10-02 Takeda Pharmaceutical Company Limited 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors
EP3033336B1 (en) 2013-08-14 2018-05-30 Kalvista Pharmaceuticals Limited Inhibitors of plasma kallikrein
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
JP6943857B2 (ja) 2015-12-22 2021-10-06 シンジェンタ パーティシペーションズ アーゲー 有害生物防除活性ピラゾール誘導体
CN108164446A (zh) * 2016-01-26 2018-06-15 绍兴瑞康生物科技有限公司 一种羧酰胺类化合物及其制备方法和应用
US10590084B2 (en) 2016-03-09 2020-03-17 Blade Therapeutics, Inc. Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof
HRP20201131T1 (hr) 2016-05-31 2020-10-30 Kalvista Pharmaceuticals Limited Derivati pirazola kao inhibitori kalikreina plazme
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
WO2018009417A1 (en) 2016-07-05 2018-01-11 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
CA3038331A1 (en) * 2016-09-28 2018-04-05 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
PL3668853T3 (pl) 2017-08-16 2022-01-31 Glaxosmithkline Intellectual Property Development Limited Nowe związki
SMT202200112T1 (it) 2017-11-29 2022-05-12 Kalvista Pharmaceuticals Ltd Forme di dosaggio comprendenti un inibitore della callicreina plasmatica
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
MX2020010033A (es) * 2018-03-28 2020-10-14 Blade Therapeutics Inc Moduladores calpaina y usos terapeuticos de los mismos.
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
EP4010333A1 (en) 2019-08-09 2022-06-15 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH21213A (en) 1984-10-26 1987-08-21 Fujisawa Pharmaceutical Co Benzene- and pyrazole- fused heterocyclic compound and pharmaceutical composition comprising the same
US4826835A (en) 1985-10-23 1989-05-02 Rorer Pharmaceutical Corporation Pyridyl-pyridazinone and pyridyl-pyrazolinone compounds and their use in the treatment of congestive heart failure
US4743608A (en) 1986-07-15 1988-05-10 Rorer Pharmaceutical Corporation Pyridone-pyridyl-imidazolyl and triazolyl compounds and their use as cardiotonic agents
US4888352A (en) 1989-03-22 1989-12-19 Sterling Drug Inc. 3,4, or 5-aryl-1H-pyrazole-1-alkanamides as antiarrhythmic agents, compositions and use
GB9412603D0 (en) * 1994-06-23 1994-08-10 Sandoz Ltd Organic compounds
DE19642591A1 (de) 1996-10-15 1998-04-16 Basf Ag Neue Piperidin-Ketocarbonsäure-Derivate, deren Herstellung und Anwendung
DE19650975A1 (de) 1996-12-09 1998-06-10 Basf Ag Neue heterocyclisch substituierte Benzamide und deren Anwendung
PL334059A1 (en) 1996-12-11 2000-01-31 Basf Ag Ketone benzamides useful as calpain inhibitors
US6127556A (en) 1996-12-31 2000-10-03 G. D. Searle & Co. Epoxide formation by continuous in-situ synthesis process
US6083944A (en) * 1997-10-07 2000-07-04 Cephalon, Inc. Quinoline-containing α-ketoamide cysteine and serine protease inhibitors
JP4621351B2 (ja) * 1998-04-20 2011-01-26 アボット ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト カルパインインヒビターとしての複素環式的に置換されたアミド
EP1080083A1 (de) 1998-04-20 2001-03-07 Basf Aktiengesellschaft Neue heterocyclisch substituierte amide mit cystein-protease hemmender wirkung
DE19818614A1 (de) 1998-04-20 1999-10-21 Basf Ag Neue substituierte Amide, deren Herstellung und Anwendung
DE19817459A1 (de) * 1998-04-20 1999-10-21 Basf Ag Neue heterozyklische substituierte Amide, Herstellung und Anwendung
DE19817461A1 (de) 1998-04-20 1999-10-21 Basf Ag Neue substituierte Benzamide, deren Herstellung und Anwendung
WO1999054310A2 (de) 1998-04-20 1999-10-28 Basf Aktiengesellschaft Neue substituierte amide, deren herstellung und anwendung
IL139357A0 (en) * 1998-05-25 2001-11-25 Basf Ag New heterocyclically substituted amides, their production and their use
AR018915A1 (es) * 1998-06-24 2001-12-12 Smithkline Beecham Corp Inhibidores de proteasas diacilhidrazinicos, composicion farmaceutica que la comprenden, usos de los mismos para la manufactura de un medicamento, unprocedimiento de fabricacion de dichos compuestos
AU2001245764A1 (en) * 2000-03-15 2001-09-24 Axys Pharmaceuticals, Inc. Novel compounds and compositions as protease inhibitors
JP2001261675A (ja) 2000-03-21 2001-09-26 Mitsui Chemicals Inc ピラゾリン誘導体またはテトラヒドロピリダジン誘導体を含有する医薬
US6995162B2 (en) * 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
DE10114762A1 (de) 2001-03-26 2002-10-02 Knoll Gmbh Verwendung von Cysteinprotease-Inhibitoren
US20030232863A1 (en) * 2002-03-05 2003-12-18 Bayly Christopher I. Cathepsin cysteine protease inhibitors
EP1610263A1 (en) 2004-06-18 2005-12-28 Sicpa Holding S.A. Item carrying at least two data storage elements
WO2006080439A1 (ja) 2005-01-28 2006-08-03 Taisho Pharmaceutical Co., Ltd. 三環性化合物
MY147780A (en) * 2006-12-29 2013-01-31 Abbvie Deutschland Carboxamide compounds and their use as calpain inhibitors
TWI453019B (zh) * 2007-12-28 2014-09-21 Abbvie Deutschland 甲醯胺化合物

Also Published As

Publication number Publication date
AU2007341232A1 (en) 2008-07-10
JP5295976B2 (ja) 2013-09-18
TW200845979A (en) 2008-12-01
US7728012B2 (en) 2010-06-01
EP2439205A1 (en) 2012-04-11
WO2008080969A1 (en) 2008-07-10
CA2673580A1 (en) 2008-07-10
ATE544758T1 (de) 2012-02-15
AR064693A1 (es) 2009-04-22
PE20081609A1 (es) 2008-11-12
DK2439205T3 (da) 2015-06-22
MY147780A (en) 2013-01-31
ES2536626T3 (es) 2015-05-27
IL231463A (en) 2016-02-29
ES2381879T3 (es) 2012-06-01
IL231463A0 (en) 2014-04-30
GT200900186A (es) 2012-03-16
EP2121653A1 (en) 2009-11-25
RU2009129119A (ru) 2011-02-10
US20130245003A1 (en) 2013-09-19
AR077477A2 (es) 2011-08-31
TWI405571B (zh) 2013-08-21
EP2121653B1 (en) 2012-02-08
US9139557B2 (en) 2015-09-22
AU2007341232B2 (en) 2013-01-31
CL2007003879A1 (es) 2008-07-04
BRPI0721298A2 (pt) 2014-03-25
KR20150090282A (ko) 2015-08-05
CN101616908A (zh) 2009-12-30
KR20090097205A (ko) 2009-09-15
IL199447A (en) 2014-04-30
ECSP099476A (es) 2009-07-31
CA2673580C (en) 2015-11-24
KR20150090281A (ko) 2015-08-05
JP2010514738A (ja) 2010-05-06
US20080234330A1 (en) 2008-09-25
KR101578674B1 (ko) 2015-12-18
RU2485114C2 (ru) 2013-06-20
US8436034B2 (en) 2013-05-07
UA100501C2 (uk) 2013-01-10
RU2013104459A (ru) 2014-08-10
US7799809B2 (en) 2010-09-21
EP2439205B1 (en) 2015-03-11
CO6190617A2 (es) 2010-08-19
NZ577719A (en) 2012-06-29
US20080234329A1 (en) 2008-09-25
NZ599860A (en) 2013-09-27
PT2439205E (pt) 2015-07-16
HK1138833A1 (en) 2010-09-03
UY30850A1 (es) 2008-07-31
PL2439205T3 (pl) 2015-08-31
US20100298326A1 (en) 2010-11-25
CN101616908B (zh) 2014-09-10

Similar Documents

Publication Publication Date Title
MX2009007050A (es) Compuestos de carboxamida y su uso como inhibidores de calpaina.
NZ596000A (en) Carboxamide compounds and their use as calpain inhibitors
TW200626601A (en) Novel compounds
PT1585739E (pt) Arilciclopropilacetamidas substitu?das como activadores da glucocinase
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
WO2007139856A3 (en) Heterobicyclic metalloprotease inhibitors
MY146111A (en) Acylaminopyrazoles as fgfr inhibitors
WO2006028958A3 (en) Pyridyl inhibitors of hedgehog signalling
MX2009004441A (es) Derivados de indazol utiles como inhibidores de las isoformas de higado.
WO2006128184A3 (en) Pyrimidine or triazine fused bicyclic metalloprotease inhibitors
MX2009005217A (es) Compuestos heterociclicos que contienen nitrogeno y metodos de uso de los mismos.
MX2007000505A (es) Derivados de oxindol sustituidos y medicamentos que contienen los mismos.
MXPA05010521A (es) Inhibidores de cinasa de amida de bifenilcarboxilica p38.
MX336637B (es) Compuestos carboxamida y su uso como inhibidores de calpaina.
GEP20094638B (en) Benzimidazolone carboxylic acid derivatives
GB0308201D0 (en) Novel compounds
UA96969C2 (en) Acylaminopyrazoles as fgfr inhibitors
WO2007047646A3 (en) Substituted dihydro-isoindolones useful in treating kinase disorders
MXPA06004308A (es) Isopentilcarboxanilidas para la lucha contra los microorganismos indeseables.
GB0412314D0 (en) Compounds
TW200628153A (en) Novel compounds
IL189286A0 (en) Novel cysteine protease inhibitors and their therapeutic applications
MX2013006419A (es) Compuestos carboxamida y su uso como inhibidores de calpaina v.
IL161842A0 (en) 2-Amino-4-heteroarylethyl-thiazoline derivatives and their use as inhibitors of inducible no-synthase
TW200612940A (en) Substituted tetrahydroisoquinolines as mmp inhibitors, process for their preparation and their use as medicament

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights